Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

US11213586B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Changyu Wang · Union City, US
• Nils Lonberg · Woodside, US
• Alan J. Korman · Piedmont, US
• Mark J. Selby · San Francisco, US
• Mohan Srinivasan · Cupertino, US
• Karla A. HENNING · Milpitas, US
• Michelle Minhua HAN · Piedmont, US
• Guodong Chen · East Brunswick Township, US
• Richard Y. Huang · Princeton, US
• Indrani Chakraborty · Fremont, US
• Haichun Huang · Fremont, US
• Susan WONG · Fremont, US
• Huiming LI · Lexington, US
• Bryan C. BARNHART · San Francisco, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Ming Lei · Princeton, US
• Liang Schweizer · Shanghai, CN
• Sandra V. HATCHER · Fryeburg, US
• Arvind Rajpal · San Francisco, US

Key dates

• Filing date: Nov 17, 2016
• Grant date: Jan 4, 2022
• Expiry date: Jun 18, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.